Discovery of Hypoglycemic and Cardiovascular Drugs as Effective Inhibitors on Human Pancreatic Lipase
Chemistry & Biodiversity · 2025
DOI: 10.1002/cbdv.202500381 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemistry & Biodiversity, 2025. Verfasst von Bing-Jie Liang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Cardiovascular Agents, Drug Discovery, Enzyme Inhibitors, Hypoglycemic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben.
Abstract (Originalsprache)
Obesity is closely related to the occurrence and development of many diseases, such as diabetes, hypertension, and hyperlipidemia. As an important digestive enzyme, human pancreatic lipase (hPL) is involved in the metabolism and absorption of dietary fat and is a key target of overweight and obesity. Therefore, the inhibition of hPL enzyme is a feasible strategy for the prevention and treatment of obesity. In this study, we collected a series of marketed hypoglycemic and cardiovascular drugs and evaluated their inhibitory activity against hPL. Among them, ticagrelor (HC‐14), prasugrel (HC‐18), amlodipine (HC‐26), simvastatin (HC‐32), and lovastatin (HC‐33) had strong inhibitory activity against hPL. In order to further clarify the inhibition mechanism, inhibition kinetics and molecular docking were carried out, and results revealed that HC‐14 was a mixed inhibitory manner on hPL activity. HC‐14 also showed similar inhibitory effect on human carboxylesterase 2 (hCES2), but poor inhibitory effect on other five serine hydrolases. Further studies showed that HC‐14 significantly inhibited hPL activity in AR42J cells, resulting in dose‐dependent inhibition. Overall, the above results suggest that ticagrelor is a cardiovascular drug that inhibits hPL, which also provides an important reference for the search and development of other drugs for the treatment of obesity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
- Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
- College of Pharmacy, Dalian Medical University, Dalian, Liaoning Province, China.
- Collaborative Innovation Center of Tumor Marker Detection Technology, Equipment and Diagnosis Therapy Integration in Universities of Shandong, Shandong Province Key Laboratory of Detection Technology for Tumor Makers, S…
- SPH Xing Ling Sci. & Tech. Pharmaceutical Co., Ltd., Shanghai, China.
ORCID-Profile: Li-Wei Zou
Zitieren
APA
Liang, B. J., Dong, L. X., Yu, Y., Zhang, J., Wang, D. D., He, W. Y., Wang, S. X., & Zou, L. W. (2025). Discovery of Hypoglycemic and Cardiovascular Drugs as Effective Inhibitors on Human Pancreatic Lipase. Chemistry & Biodiversity. https://doi.org/10.1002/cbdv.202500381
Vancouver
Liang BJ, Dong LX, Yu Y, Zhang J, Wang DD, He WY, et al. Discovery of Hypoglycemic and Cardiovascular Drugs as Effective Inhibitors on Human Pancreatic Lipase. Chemistry & Biodiversity. 2025. doi:10.1002/cbdv.202500381
BibTeX
@article{Liang2025,
author = {Liang, Bing-Jie and Dong, Le-Xuan and Yu, Yang and Zhang, Jing and Wang, Dan-Dan and He, Wen-Yao and Wang, Shu-Xia and Zou, Li-Wei},
title = {Discovery of Hypoglycemic and Cardiovascular Drugs as Effective Inhibitors on Human Pancreatic Lipase},
journal = {Chemistry & Biodiversity},
year = {2025},
doi = {10.1002/cbdv.202500381}
}
EUVIMED